New antibiotic shows promise for scrub typhus fever
NCT ID NCT07513103
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This study tested whether the antibiotic tigecycline works better than the standard drug doxycycline for scrub typhus, a bacterial infection spread by mites. Thirty-one hospitalized patients were randomly assigned to receive either tigecycline or doxycycline. Researchers measured how quickly fever went away and tracked any side effects to see if tigecycline is a safe and effective alternative.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tigecycline (compared to doxycycline)
- What this could lead to
- If tigecycline works better, it could offer a new treatment option for scrub typhus, potentially reducing fever faster.
- What could go wrong
- This is a small, completed study with only 31 participants, so results may not apply broadly. Tigecycline may cause side effects or not be more effective than the standard drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
27 people
The number who actually took part.
- Started
-
Nov 2022
- Finished
-
Jan 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Hospitalization with a fever of 37.5℃ or higher (tympanic temperature measurement standard) and rash or scabs suspected of tsutsugamushi syndrome * If an infectious disease specialist makes a clinical judgment and diagnoses scrub typhus * A person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing a detailed explanation of this clinical study and fully understanding it Exclusion Criteria: * Patients with severe complications such as respiratory failure, pneumonia, and encephalitis (researcher determines final exclusion) * Patients with chronic renal dysfunction * Underweight people weighing less than 45Kg * Immunodeficiency: Long-term use of steroids or other immunosuppressive drugs, patients undergoing chemotherapy, etc. (Researcher determines final exclusion) * Pregnant women * Women and men of childbearing potential who are planning to become pregnant during the clinical study period and for 3 months after the end of the clinical study, or who are unwilling to use the following appropriate contraceptive methods\* \* Intrauterine device \[IUD (Intrauterine device), barrier contraception method including spermicide (for female contraceptive vaginal diaphragm/vaginal sponge sponge/cervical cap) and double barrier method (for male use) Excluding simultaneous use of condoms and female condoms), sterilization (vasectomy, vasectomy, tubal ligation, etc.) * If you cannot take the medicine orally * Patients already using other anti-rickettsial drugs (rifampin, chloramphenicol, macrolides, quinolones, tetracyclines) * Patients with shock or multiple organ failure requiring vasopressor/vasoconstrictor, impaired consciousness, respiratory failure requiring mechanical ventilation, and renal dysfunction requiring hemodialysis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Scrub typhus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dankuk university hospital
Cheonan, Chungcheongnam-do, 31116, South Korea
-
Gyeonsang National University Hospital
Jinju, 52727, South Korea
-
Inha university hospital
Incheon, 22332, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.